The chemical class referred to as SEMA4G Modulators encompasses a diverse range of compounds that interact with or affect the SEMA4G protein, a member of the semaphorin family known for its involvement in neural development, immune regulation, and possibly in oncological processes. The exploration of these modulators is crucial in understanding the intricate mechanisms of SEMA4G-mediated signaling and its broader implications in various biological processes. The development and characterization of these compounds involve advanced methodologies in molecular biology, biochemistry, and pharmacology, focusing on SEMA4G's role in cell signaling, particularly its interactions with cell surface receptors and subsequent intracellular pathways.
The initial phase in identifying and developing SEMA4G modulators involves a comprehensive understanding of SEMA4G's structure, function, and its interactions within the cell. This includes identifying the binding sites and domains responsible for its interaction with receptors, as well as understanding the downstream signaling pathways triggered by these interactions. Computational methods, such as molecular docking and virtual screening, play a crucial role in this phase. These in silico techniques are instrumental in predicting how various chemical entities might interact with SEMA4G, allowing for the identification of compounds that can potentially modulate its activity. Following computational predictions, experimental validation is conducted using biochemical assays to confirm the interactions between SEMA4G and the identified compounds. These assays measure the binding affinity, kinetics, and the functional impact of these compounds on SEMA4G's activity. Furthermore, cell-based assays are essential in elucidating the broader biological impact of SEMA4G modulation. These assays help determine whether the modulation leads to changes in the processes where SEMA4G is a key player, such as axonal guidance, immune cell regulation, and angiogenesis in the context of tumor growth. The specificity and selectivity of these compounds are also rigorously tested to ensure that their effects are primarily focused on SEMA4G-related pathways. The exploration of SEMA4G modulators not only deepens our understanding of SEMA4G's biological roles but also contributes to the broader field of molecular pharmacology. These compounds serve as vital tools in dissecting the complex networks of protein interactions and signaling pathways in cells, providing insights into the mechanisms of cell signaling and regulation, and enhancing our understanding of the physiological and pathological processes in which SEMA4G is involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
Fingolimod could possibly inhibit SEMA4G by altering lymphocyte egress, affecting SEMA4G's role in immune regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, as an mTOR inhibitor, could possibly inhibit SEMA4G by impacting cellular processes and signaling pathways associated with it. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporine A, an immunosuppressant, could possibly inhibit SEMA4G-mediated immune functions by affecting T-cell activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, could possibly inhibit SEMA4G by affecting pathways involved in cell proliferation and migration. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, could possibly inhibit SEMA4G's role in cell survival and angiogenesis by impacting relevant signaling pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib, an EGFR inhibitor, could possibly inhibit SEMA4G by affecting cellular pathways, particularly in progression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, could possibly inhibit SEMA4G by affecting protein degradation pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a kinase inhibitor, could possibly inhibit pathways associated with SEMA4G, especially in growth and angiogenesis. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide, an immunomodulatory compound, could possibly inhibit SEMA4G-mediated immune regulation pathways. | ||||||